S'abonner

Long-term low-dose cyclosporine therapy for severe psoriasis: Effects on renal function and structure - 11/09/11

Doi : 10.1016/S0190-9622(96)90726-4 
Nicholas J Lowe, MD , a, b, Joshua M Wieder, MD a, b, Alan Rosenbach, MD a, Kent Johnson, MD c, Robin Kunkel, MS c, Carol Bainbridge, MD, PhD d, Teresa Bourget, BS a, Ivailo Dimov, MD a, Karen Simpson, MD a, Edwin Glass, MD b, Morris T Grabie, MD b
a From Skin Research Foundation of California, Santa Monica, California, USA 
b St. John's Hospital and Health Center, Santa Monica, California, USA 
c the University of Michigan, Ann Arbor, Michigan, USA 
d Sandoz Research Institute, East Hanover, New Jersey, USA 

Reprint requests: Nicholas J. Lowe, MD, Clinical Professor of Dermatology, UCLA School of Medicine, Skin Research Foundation of California, 2001 Santa Monica Blvd. #490W, Santa Monica, CA 90404-2115.

Abstract

Background: The effectiveness of cyclosporine in the treatment of severe psoriasis is well known.

Objective: We evaluated the efficacy and toxicity of systemic cyclosporine in patients with severe psoriasis, observing short-term (12 weeks) and long-term (3 to 5 years) effects.

Methods: To further elucidate efficacy and safety, 42 patients with severe psoriasis were treated initially with cyclosporine 5 to 6 mg/kg per day for 12 weeks. A subset of 14 patients continued maintenance treatment for 3.5 years to study the long-term effects of cyclosporine on renal function and structure. Renal biopsies were performed after 2.5 years and 3.5 years of treatment. Renal histologic findings were correlated with renal function.

Results: By weeks 8 and 12, 64% (n = 27) and 86% (n = 36) of patients, respectively, were rated clear or almost clear of the psoriasis. However, a subpopulation of 15 patients did not respond to 5 mg/kg daily but improved when the dose was increased to 6 mg/kg daily. Clearance or near clearance was achieved in 67% of this subpopulation after 4 weeks. For the 29 patients whose glomerular filtration rate (GFR) was measured, mean GFR fell by 7% from baseline to week 4 (p < 0.05). This change was reversible when dosage was reduced by 1 mg/kg per day in each of these patients. Patients older than 45 years of age experienced significant elevation of mean diastolic blood pressure and had reduced GFR and increased serum creatinine. After 2.5 years, of the 14 patients who continued maintenance treatment, two had biopsy specimens that showed moderate interstitial fibrosis and tubular atrophy. The remainder showed only minimal to mild structural damage. After 3.5 years of cyclosporine treatment, repeat renal biopsy specimens revealed slight increases in structural changes in nine subjects. These changes correlated with increasing age and drug-induced hypertension.

Conclusion: We conclude that 5 mg/kg of cyclosporine daily is usually an effective initial dose for psoriasis. Patients who do not respond will often benefit from elevation of the dose to 6 mg/kg daily. Older patients experience cyclosporine-induced hypertension and changes in renal function and structure more frequently than do younger patients.

Le texte complet de cet article est disponible en PDF.

 Supported by a grant from Sandoz Research Institute, East Hanover, N.J.


© 1996  Publié par Elsevier Masson SAS.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 35 - N° 5P1

P. 710-719 - novembre 1996 Retour au numéro
Article précédent Article précédent
  • A characteristic eruption associated with ifosfamide, carboplatin, and etoposide chemotherapy after pretreatment with recombinant interleukin-1⍺
  • Ronald Prussick, Thomas D Horn, Wyndham H Wilson, Maria C Turner
| Article suivant Article suivant
  • Chlorambucil is an effective corticosteroid-sparing agent for recalcitrant pyoderma gangrenosum
  • Jyoti B Burruss, Evan R Farmer, Jeffrey P Callen

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.